Many substances are active in in vitro tests for estrogenic activity, but data from multigenerational and other toxicity studies are not available for many of those substances. Controversy has arisen, therefore, concerning the likelihood of adverse health effects. Based on a toxic equivalence factor risk assessment approach, some researchers have concluded that exposure to environmental estrogens is not associated with estrogen receptor (ER)-mediated health effects. Their rationale cites the low potency of these compounds in in vitro assays relative to estradiol, and the widespread exposure to pharmaceutical, endogenous, and dietary estrogens. This reasoning relies on two assumptions: that the relative estrogenic potency in in vitro assays is predictive of the relative potency for the most sensitive in vivo estrogenic effect; and that all estrogens act via the same mechanism to produce the most sensitive in vivo estrogenic effect. Experimental data reviewed here suggest that these assumptions may be inappropriate because diversity in both mechanism and effect exists for estrogenic compounds. Examples include variations in ER-ligand binding to estrogen response elements, time course of nuclear ER accumulation, patterns of gene activation, and other mechanistic characteristics that are not reflected in many in vitro assays, but may have significance for ER-mediated in vivo effects. In light of these data, this report identifies emerging methodological issues in risk assessment for estrogenic compounds: the need to address differences in in vivo end points of concern and the associated mechanisms; pharmacokinetics; the crucial role of timing and duration of exposure; interactions; and non-ER-mediated activities of estrogenic compounds. Environ Health Perspect 1 05(Suppl 3): 655-663 (1997) 
Introduction
A number of plant-derived and anthropogenic compounds are now known to have estrogenic activity (1) (2) (3) . These compounds include plant-derived dietary constituents as well as plasticizers, surfactants, constituents of detergents, pesticides, and a variety of other chemicals (1, (4) (5) (6) . Identification of estrogenic activity is primarily based on results of in vitro assays that rely on indicators such as estrogen receptor (ER) binding, gene transcription, or cell proliferation, or on short-term in vivo assays such as uterine growth bioassays (7) .
It is well known that estrogenic activity may be observed due to direct effects of a compound binding the ER and inducing gene transcription, and to indirect effects such as induction of enzymes involved in metabolism or synthesis of endogenous estrogens (8, 9) , effects on binding of endogenous estrogens to hormone binding proteins (10) , effects on ER regulation (11) , and others. Estrogenic compounds have also OP, 4-tert-octylphenol; PCBs, polychlorinated biphenyls; SDN-POA, sexually dimorphic nucleus in the preoptic area of the hypothalamus; SHBG, sex hormone-binding globulin; 2,3,7,8-TCDD, 2,3,7,8-tetrachlorodibenzo-pdioxin; TEF, toxic equivalence factor. been reported to have other effects, such as involvement in other cell signaling pathways that may stimulate receptor-mediated estrogen action, e.g., protein kinase C (2, 12, 13) , inhibition of microtubule polymerization (14) , or inhibition of gap-junctional intercellular communitation (GJIC) (15) .
Exposure to estrogenic chemicals could be substantial because of their widespread use, yet data from sensitive in vivo studies are not available for many of them. Reproductive toxicity studies in animals are typically required for pesticides and can detect certain endocrine system effects; however, many chemicals in common use have not been screened for endocrine activity or examined in reproductive toxicity studies. Data from multigenerational toxicity studies in animals that allow identification of developmental effects are available for relatively few chemicals. Furthermore, new protocols for conducting multigenerational studies have identified more sensitive end points for endocrine effects on development than have been utilized in traditional protocols (16) (17) (18) .
Public concern about the potential health effects of exposure to environmental pollutants with estrogenic activity, often referred to as environmental estrogens, has created pressure for scientists to make predictions about the significance of current exposures to environmental estrogens in the absence of good information on exposure, effects, or dose response (19) (20) (21) . Predicting human health effects of exposure to estrogenic compounds involves synthesizing assay information on the activities of a broad spectrum of estrogenic compounds to which humans are simultaneously exposed, including endogenous and pharmaceutical estrogens, as well as phytoestrogens and environmental estrogens. Many types of compounds have been characterized as having estrogenic activity; predicting health effects associated with one class (environmental estrogens) requires consideration of the activities of, and interactions with, the other dasses of estrogenic compounds.
To date, predictions of human health effects of exposure to these compounds have covered a wide range. Some researchers have hypothesized that there may be an association with serious health effects such as breast cancer and fertility (3, (22) (23) (24) (25) . Others, however, have conduded that exposure to environmental estrogens will not be associated with any estrogen-mediated adverse health effects in humans because of the low potency of those compounds in the in vitro assays relative to endogenous estradiol, the high levels of circulating endogenous estrogen, and the fact that so many plant-derived estrogenic compounds are present at high concentrations in food (26) . Although these factors are important to consider in predicting the health effects of exposure to compounds with estrogenic activity, the conclusion that environmental estrogens will not be associated with adverse health effects relies on several assumptions that must be carefully examined (27 (28) .
In the case of dioxin, use of the TEF approach was predicated on the significant finding that the chemical has to bind to a receptor before causing any toxic effects (29) . In (34, 35) . In more recent experiments, it increased uterine wet and dry weights but did not cause depletion of cytosolic ER, accumulation of nuclear ER, or uterine hyperplasia and DNA synthesis, all characteristic estrogen responses (36) . Lack of uterine DNA synthesis was observed in these experiments even after multiple injections of coumestrol, indicating that coumestrol was not like estriol or other short-acting or weak endogenous estrogens, which have been shown to mimic more potent estrogens following chronic dosing. Whitten et al. (37) investigated the influence of dietary coumestrol on estradiol action in the rat uterus and found that coumestrol acted additively with estradiol for some end points (increased uterine weight and decreased cytosolic ER binding) in these experiments but also dampened estradiol's induction of progestin receptors, uterine protein, and nuclear estrogen receptor binding (37) . Thus, in this system coumestrol's activities do not appear to be identical to those of estradiol, even after multiple doses; and coumestrol modulates the activity of endogenous estradiol.
In the male mouse treated neonatally with DES, adult treatment with 17,-estradiol induces prostatic metaplasia while adult treatment with coumestrol or soy does not induce metaplasia or prevent 173-estradiol-induced metaplasia (38).
Makela et al. refer to coumestrol as a partial estrogen agonist in this system because it weakly induced c-fos expression, though estrogenic effects of coumestrol were generally missing in adult male neo-DES mice (38) . These researchers also found that male mice fed a soy diet from fertilization onward and neonatally treated with DES had reduced dysplasia in the prostate compared with mice not fed soy diets; this effect was attributed to antiestrogenic activity of soy (39) . In summary, coumestrol appears to be quite similar to 17p-estradiol in some systems under some conditions (e.g., MCF-7 cells, immature rat uterus), but acts as an incomplete estrogen or even modulates and dampens the effects of endogenous estrogens in other systems (male mouse, female rat). These variations in activity cannot necessarily be predicted from in vitro assays, but may have implications for in vivo response.
In another study, the effect of prenatal exposure to genistein, also a component of soy, was compared with that of DES and estradiol in rats (40) . All animals except DES-treated females had smaller anogenital distance than controls. Genisteintreated females had decreased volume of sexually dimorphic nucleus in the preoptic area of the hypothalamus (SDN-POA) while DES and estradiol-treated females had increased SDN-POA volume compared to controls. In addition, genistein had a unique effect in that it delayed puberty onset. DES (but not estradiol or genistein) increased the incidence of atypical vaginal cycles (40) . Thus (44) . It is well known that different estrogenic compounds act through different mechanisms and produce multiple and varied effects. We are reviewing this information here because it needs to be considered when predicting in vivo health effects based on extrapolation from screening tests for estrogenic activity.
ER Dynamics: Nuclear Accumulation and Impact of Pharmacokinetics
The time course of nuclear accumulation of the ER-ligand complex has been studied in the context of efforts to understand mechanisms of estrogen-induced responses such as uterine hyperplasia (45) (46) (47) (48) (49) . Generally, researchers using a mouse or rat uterine assay have shown a biphasic increase in nuclear ER levels to follow treatment with 17p-estradiol or DES. Increase in uterine wet weight follows the time course of the biphasic nuclear ER increase, with only the second phase described as "true uterine growth" due to increased cellular DNA synthesis. The first increase in nuclear ER accumulation and uterine weight is shown 1 to 3 hr after dose, and the second increase 7 to 9 hr after dose. Weak estrogens show the early response phase only, although multiple doses of some weak endogenous estrogens mimic the effect of more potent estrogens (7) . Nuclear ER levels return to approximately control levels about 10 hr after treatment with estradiol (46) . Cytosolic ER levels decrease as nuclear ER levels increase and ultimately increase above control levels (36, 46 estrogen is apparent from their study. The weak estrogen dimethylstilbestrol (DMS) and its dimethylether DMS-(OMe)2, which does not bind ER, were tested in the assay. Acting like a typical weak estrogen, DMS induced short-term but not longterm nuclear accumulation of ER and uterine growth. The DMS-(OMe)2, which had to be metabolically activated to the weakly estrogenic DMS, induced long-term increases in nuclear ER and uterine growth because metabolic activation proceeded at a rate that simulated chronic dosing (50) . Repeated dosing with some weak estrogens can cause long-term increases in uterine growth such as those caused by more potent estrogens (above). Thus, the pharmacokinetics of estrogens can modify not only the duration of a response, but also the type of estrogenic response observed.
Patterns of ER localization after treatment with coumestrol in similar assays shows some conflicting but interesting differences from ER localization after estradiol, estriol, or DES treatment. While Whitten et al. (33) found that coumestrol in the diet of immature rats increased nuclear ER concentrations, Markaverich et al. (36) reported that coumestrol failed to cause substantial nuclear accumulation of ER in ovariectomized rats, although it did cause increase in uterine wet and dry weights. Markaverich et al. (36) show a slight increase in nuclear ER after coumestrol treatment, with levels returning to control levels in less than 5 hr and then decreasing slightly below control levels through 24 hr. Treatment with a higher dose of coumestrol did not modify this pattern or increase nuclear ER, indicating that coumestrol was not able to function as a more potent estrogen in this system. Estradiol stimulation, on the other hand, caused a significant increase in nuclear ER that returned to control levels by 5 hr after treatment. Coumestrol appeared to induce long-term increases in cytosolic ER, which increased slowly but continuously over the 24 hr during which measurements were made.
In an experiment looking at coumestrol modulation of estradiol action in the rat uterus, Whitten et al. (37) found that animals that received coumestrol along with physiologic doses of estradiol for 90 hr had lower levels of nuclear ER than controls. When these animals were challenged with a single estradiol dose, the coumestroltreated animals produced a smaller increase in nuclear ER than controls (37) . Although there is conflicting evidence about whether coumestrol alone substantially increases nuclear ER (33, 36) , it does appear that a coumestrol diet diminished the nuclear ER accumulation after estradiol treatment (37) . In another example of the differential abilities of various estrogens to induce nuclear accumulation, Martin et al. (51) reported that in MCF-7 cells, genistein and coumestrol (both soy derivatives) were less effective at translocating ER to the nucleus than zearalenol (a mycotoxin) and estradiol.
Hammond et al. (52) reported that the organochlorine pesticide chlordecone is estrogenic and interacts with rat uterine estrogen receptors. In experiments comparing estradiol and chlordecone, nuclear ER levels increased quickly following estradiol treatment and then decreased to nearly control levels by 12 hr posttreatment. Chlordecone, on the other hand, increased nuclear ER slowly, reaching maximum at 36 hr and maintaining that level through the end of the experiment at 48 hr. The long half-life of chlordecone, therefore, appears to moderate the relative potency of the compound in vivo, but may also moderate the qualitative estrogenic effect due to the potential importance of the time course of ER-ligand activity in the nucleus in determining the nature of the estrogenic response. For example, pharmacokinetics of the ER-ligand complex could affect the length of time that expression of some genes remain elevated (31) .
In another example of how different estrogens exhibit different pharmacokinetics with respect to nuclear accumulation of ER, administration of o,p'-DDT to immature female rats caused translocation of ER to the nucleus that was maximal 3 hr after treatment; estradiol in this system caused maximal nuclear ER 1 hr after treatment (53) . In experiments comparing the time course of uterine weight increases in rats following treatment with amsonic acid and DES, both test compounds induced an extended increase relative to estriol (6) . Amsonic acid is an optical brightening agent that was tested for estrogenic activity after reports of sexual impotence among exposed factory workers (6) .
It has been observed that the duration of nuclear ER accumulation affects the response observed, although this relationship has been explored only for a few endogenous and pharmaceutical estrogens (45) (46) (47) (48) (49) (50) . The fact that certain phytoestrogens and environmental estrogens show variation in timing of nudear ER accumulation (33,36,37,52,53) strongly suggest that it may be important to consider timing and duration of dosing in determining effect. This is important because it is not clear that the effects of increasing the duration of nuclear accumulation of activated ER are equivalent to the effects of simply increasing the dose of estradiol. Pharmacokinetic considerations are also important, therefore, in determining not only dose to target tissue, but potentially also in characterizing the end point expected.
Consideration of Effects on Estrogen Synthesis, Metabolism, and Bioavailability
Because estrogen synthesis and metabolism in vivo are regulated by many factors including endogenous estrogen, it is not surprising that exogenous estrogens often also affect these regulatory mechanisms (8, 23) . In attempting to predict health effects of exposure to xenobiotic compounds, it is important to consider the ability of a compound to alter the endogenous hormone environment by influencing synthesis or metabolism of endogenous estrogens (and other endogenous steroids). Of course, these effects involve mechanisms that do not necessarily involve binding ER. Some compounds cause changes in levels of cytochrome P450 enzymes that are involved in estrogen metabolism (indirect estrogenic effects) (9, 23, 54) , while other compounds that induce ER-mediated gene transcription also affect synthesis or metabolism of estradiol (8) . Effects on the endogenous hormone environment cannot be accounted for by assuming that the consequences of exposure to exogenous estrogens are simply an extension of exposure to endogenous hormone, because the effects on hormone synthesis and metabolism vary among estrogenic compounds. Although it is not surprising that any compounds have multiple effects, consideration of multiple effects for estrogenic compounds may be particularly important because of the resulting difficulty of predicting interference with normal signaling processes.
For example, Bradlow et al. (23) have shown that exposure to a number of compounds, many of which are estrogenic, can affect the metabolism of 17p-estradiol by shifting the ratio of two metabolites, 2-hydroxyestrone and 16a-hydroxyestrone. This effect may be important for predicting health effects because the 16a-hydroxy metabolite is genotoxic and a potent estrogen, while the 2-hydroxyestrone metabolite is not reported to be genotoxic and is only very weakly estrogenic (55 reported that the plant-derived flavonoid quercetin, which increases the severity of estradiol-induced tumorigenesis in hamster kidney, operates by increasing the formation of the catechol estradiol metabolite 4-hydroxyestradiol, which may undergo redox cycling and generate free radicals (54).
Makela et al. (8) reported that several plant estrogens, including coumestrol and genistein, reduce the conversion of estrone to 17p-estradiol by inhibiting the estrogenspecific enzyme 17p-hydroxysteroid oxidoreductase Type 1 in vitro, but zearalenone and DES did not inhibit this enzyme. Thus, the phytoestrogens coumestrol and genistein, which have been reported by some as incomplete estrogens incapable of inducing all the effects of 170-estradiol (36, 40) , may also decrease availability of active endogenous estrogen by inhibiting its synthesis. These types of differences in the combination of ER-mediated and other estrogen-related effects of exogenous compounds may have significant impacts on their potential health effects.
Differences in the bioavailability of compounds in vivo and effects of estrogenic compounds on the bioavailability of endogenous estrogens are additional factors that will modulate toxicity in vivo. These factors should also be considered in predictions of health effects of exposure to these compounds. One of the most important modulators of the availability of endogenous estrogens may be the serum-binding proteins like sex hormone-binding globulin (SHBG) . While this protein can modulate the availability of endogenous estrogens, in most cases its ability to modulate the availability of exogenous estrogens remains to be explored. SHBG appears not to bind many environmental estrogens (16, 56) , but estrogenic compounds may affect SHBG binding to endogenous estrogens (57) . This observation offers another mechanism by which exogenous estrogens may modulate endogenous estrogen activity.
The importance of the steroid hormone microenvironment within cells has been recognized and mechanisms of regulation of enzymes involved in estrogen metabolism and synthesis are being explored at the level of the target tissue (58) (59) (60) (61) (44) .
In addition, researchers have reported the ability of DES, some stilbene estrogens, and the common environmental estrogen bisphenol-A, to inhibit microtubule formation (14) . Endogenous estrogens and phytoestrogens tested in this cell-free assay did not have that effect. Inhibition of microtubules in intact cells may lead to the induction of micronuclei and aneuploidy, which may play a role in estrogen-mediated carcinogenesis (14) .
The idea that estrogens may regulate cellular function at sites other than specific gene-regulating receptors has been explored recently (13, 65) . Plasma membraneresident forms of ER have been proposed to explain observations of cellular responses to estrogen that occur within minutes and so cannot be explained through gene transcription (65) . In addition, other researchers have shown that chemicals-that activate peptide growth factor signaling systems, such as protein kinase-C activators, can also induce ERE-dependent transcription (12) . These researchers showed that a protein kinase-C activator acted synergistically with 173-estradiol to induce ERE-dependent transcription. They also showed that epidermal growth factor, which produces estrogenlike effects in the mouse reproductive tract, increases levels of nuclear ER (12) . These researchers note that the potential health effects associated with exposure to exogenous estrogens may also be observed following exposure to chemicals that could activate peptide growth factor signaling systems.
Recently researchers showed that dieldrin, DDT, and toxaphene, all of which have been reported to be estrogenic, inhibited GJIC in normal human breast epitheliel cells in a dose responsive manner. Effects of these compounds were additive, with subthreshold doses of individual compounds being effective when combined (15) . Many tumor promotors have the ability to inhibit GJIC. It is hypothesized that inhibition of GJIC may release initiated cells from suppressing effects of signals passing from surrounding normal cells (15) .
The effects of mixtures of compounds may be particularly striking for estrogenic and other hormonally active compounds, and thus particularly important for risk assessment. As illustrated above, certain phytoestrogens modulate the activity of endogenous estrogens (37 estrogenic activity. Screening tests are useful to identify compounds for further study, but must be used with caution to predict health effects or no-effect levels. Although it is not clear whether current levels of exposure to estrogenic or other hormonally active compounds in the environment are associated with health effects, it is premature to dismiss exposure to environmental estrogens as a concern for human health effects based on relative in vitro potency.
A substantial body of experimental data provides insight into differences among estrogenic compounds in terms of mechanisms of action and end points. For example, data suggest variations between compounds in ER-ligand binding to EREs (31) , time course of nuclear ER accumulation (36, 52) , patterns of gene activation (38) , and other mechanistic characteristics. These and other data presented here suggest that the assumption that relative potency in in vitro screening assays is representative of relative potency for the most sensitive ERmediated in vivo effect has not been demonstrated to be accurate.
Current toxicity testing protocols may not be adequate to identify endocrine effects, and may need to be expanded to accommodate the special challenges of risk assessment for estrogenic compounds. For example, for some estrogen-mediated end points the dose response curve is such that high-dose experiments are not likely to be predictive of low dose effects (16, 56) . Therefore, it may be necessary to broaden testing protocols to look at an extended dose-response curve. It may also be appropriate to modify protocols to evaluate an enlarged spectrum of end points, including more sensitive end points like delayed developmental or behavioral effects. For example, Vom Saal et al. (16) found territorial behavior in male mice affected by prenatal exposure to 0.001 mg/day of DES or 1 mg/day of o,p'-DDT; and Chapin et al. (17) have developed new protocols for testing a variety of endocrine, immune, and neurological effects of certain pesticides.
It is well known that timing of exposure has a substantial impact on the dose required to induce an effect. Testing protocols need to identify the most sensitive periods for exposure and to follow up for latency and multigenerational effects. In addition, timing of exposure can affect the type of response observed. For example, neonatal exposure of rats to genistein produced an enlarged SDN-POA, while prenatal exposure decreased SDN-POA volume (40) . Duration of dosing also has an important impact on patterns of nuclear accumulation of ER and resulting effects (50) , so pharmacokinetics and dosing regimes have an impact on the qualitative as well as quantitative nature of the response. Thus, consideration of time as a third axis on the dose-response curve may be particularly important for endocrine effects. The time axis could incorporate information on when in the lifecycle of the organism exposure occurs, as well as duration of exposure of the target tissue. The experimental data reviewed in this paper provide examples of the importance of both these fa4tors in determining the toxicological end points observed.
Risk assessment for estrogenic compounds must consider, among other factors, the diversity in effects observed between classes of estrogens in various animal models, the importance of pharmacokinetics, timing, and duration of exposure in modulating the spectrum of toxicological end points, the diverse (ER-and non-ER-mediated) activities of many estrogenic compounds, and the interactions between multiple compounds to which individuals are simultaneously exposed, including interactions between exogenous and endogenous factors. Emerging questions about risk assessment techniques for hormonally active compounds, therefore, may require new methods.
We propose that a focused research strategy be developed to investigate the mechanisms of action, diversity of effects, and pharmacokinetics of endocrine disrupters. This research should integrate the study of endogenous, synthetic, anthropogenic, and phytoestrogens in a focused program that will not only increase our understanding of potential health effects associated with exposure to these compounds in diet and the environment, but will provide insight into the role of endogenous hormones in breast cancer and other major health concerns.
